FCCC LOGO Faculty Publications
Vidri RJ , Howell KJ , Meyer JE , Rivard MJ , Emrich JG , Price RA , Farma JM , Turian JV , Poli J , Wang D
Initial Clinical Experience With Novel Directional Low-dose Rate Brachytherapy for Retroperitoneal Sarcoma
J Surg Res. 2021 Aug 17;268 :411-418
Back to previous list
Abstract
BACKGROUND: A novel Palladium-103 low-dose rate (LDR) brachytherapy device was developed to provide dose-escalation to the tumor bed after resection while shielding adjacent tissues. This multicenter report describes the initial experience with this device in patients with retroperitoneal sarcoma (RPS). MATERIALS AND METHODS: Patients with recurrent RPS, prior radiotherapy, and/or concern for positive margins were considered. An LDR brachytherapy dose of 20-60 Gy was administered, corresponding to biologically effective dose values of 15-53 Gy and equivalent dose values of 12-43 Gy. RESULTS: Six patients underwent implantation at four institutions. Of these, five had recurrent disease in the retroperitoneum or pelvic sidewall, one had untreated locally advanced leiomyosarcoma, two had prior external beam radiation therapy at the time of initial diagnosis, and four received neoadjuvant external beam radiation therapy plus brachytherapy. The device was easily implanted and conformed to the treatment area. Median follow-up was 16 mo; radiation was delivered to the at-risk margin with minimal irradiation of adjacent structures. No local recurrences at the site of implantation, device migration, or radiation-related toxicities were observed. CONCLUSIONS: The novel LDR directional brachytherapy device successfully delivered a targeted dose escalation to treat RPS high-risk margins. Lack of radiation-related toxicity demonstrates its safety.
Notes
1095-8673 Vidri, Roberto J Howell, Krisha J Meyer, Joshua E Rivard, Mark J Emrich, Jacqueline G Price, Robert A Farma, Jeffrey M Turian, Julius V Poli, Jaganmohan Wang, Dian Journal Article United States J Surg Res. 2021 Aug 17;268:411-418. doi: 10.1016/j.jss.2021.06.080.